A9 Dopaminergic Neuron Therapy
Parkinson's Disease
Key Facts
About Trailhead Biosystems
Trailhead Biosystems is a private, pre-revenue biotech company pioneering a platform approach to industrialize the production of induced pluripotent stem cell (iPSC)-derived human cells. Its core innovation is the High-Dimensional Design-of-Experiments (HD-DoE®) platform, which systematically optimizes differentiation protocols to generate consistent, high-quality cells for research and therapeutic use. The company is actively developing a portfolio of off-the-shelf research cells and pursuing therapeutic partnerships to advance cell therapies for neurological, metabolic, and hematological diseases. Trailhead operates as a platform and services company, offering custom differentiation and co-development partnerships to advance the regenerative medicine field.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| golexanolone | Umecrine Cognition | Preclinical |